<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Radiol Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">Radiol Case Rep</journal-id><journal-title-group><journal-title>Radiology Case Reports</journal-title></journal-title-group><issn pub-type="epub">1930-0433</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32346462</article-id><article-id pub-id-type="pmc">7182696</article-id><article-id pub-id-type="publisher-id">S1930-0433(20)30096-0</article-id><article-id pub-id-type="doi">10.1016/j.radcr.2020.03.016</article-id><article-categories><subj-group subj-group-type="heading"><subject>Musculoskeletal</subject></subj-group></article-categories><title-group><article-title>Giant cell tumor of the talus: A case report</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name><surname>Galvan</surname><given-names>Dana</given-names></name><degrees>MD, MPH</degrees><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0002"><name><surname>Mullins</surname><given-names>Carola</given-names></name><degrees>MD</degrees><email>Carola.mullins@ttuhsc.edu</email><xref rid="aff0002" ref-type="aff">b</xref><xref rid="cor0001" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au0003"><name><surname>Dudrey</surname><given-names>Ellen</given-names></name><degrees>MD</degrees><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0004"><name><surname>Kafchinski</surname><given-names>Lisa</given-names></name><degrees>MD</degrees><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0005"><name><surname>Laks</surname><given-names>Shaked</given-names></name><degrees>MD</degrees><xref rid="aff0002" ref-type="aff">b</xref></contrib><aff id="aff0001"><label>a</label>Transitional Year Department, University of Rio Grande Valley</aff><aff id="aff0002"><label>b</label>Department of Radiology, Texas Tech University Health Sciences Center El Paso, 5001 El Paso Drive, CSB-A02, El Paso, TX 79905</aff><aff id="aff0003"><label>c</label>Department of Pathology, Texas Tech University Health Sciences Center El Paso, El Paso, TX</aff><aff id="aff0004"><label>d</label>Department of Orthopedic Surgery, Texas Tech University Health Sciences Center El Paso, El Paso, TX</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#x0204e;</label>Corresponding author. <email>Carola.mullins@ttuhsc.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>22</day><month>4</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>7</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>22</day><month>4</month><year>2020</year></pub-date><volume>15</volume><issue>7</issue><fpage>825</fpage><lpage>831</lpage><history><date date-type="received"><day>18</day><month>10</month><year>2019</year></date><date date-type="rev-recd"><day>9</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>10</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The Authors. Published by Elsevier Inc. on behalf of University of Washington.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder/><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0001"><p>Giant cell tumor is a benign primary bone neoplasm which most often occurs in a periarticular location. Involvement of the bones of the foot and ankle is rare, and there have been a limited number of previous case reports involving the talus. Here we report a case of giant cell tumor of the talus, which was initially radiographically occult in a 43-year-old female, with emphasis on MRI imaging characteristics. The patient underwent surgical excision and curettage. Histological examination revealed the presence of spindle cells admixed with giant cells, confirming GCT. We further provide an overview of the radiological findings of GCT.</p><p>Giant cell tumor is a benign bone neoplasm of mesenchymal origin, identified by multinucleated giant cells <xref rid="bib0001" ref-type="bibr">[1]</xref>. GCT is locally aggressive and can destroy adjacent bone and articulations. The most commonly affected bones are the distal femur, proximal tibia, and distal radius, with an epiphyseal predominance in 90% of cases <xref rid="bib0002" ref-type="bibr">[2]</xref>. Presentations are mostly mono-ostotic, however multicentricity may occur in younger patients <xref rid="bib0003" ref-type="bibr">[3]</xref>. Very few cases have been reported in the bones of the feet, an incidence of 1%-2% have been previously reported <xref rid="bib0004" ref-type="bibr">[4]</xref>.</p><p>GCT is seen between ages 20 and 40 years, with a 56% predominance in females <xref rid="bib0003" ref-type="bibr">[3]</xref>. Although benign, 1%-9% cases may &#x0201c;metastasize&#x0201d; to the lungs. The initial treatment is surgical removal, either en bloc, or more commonly intralesional curettage and the use of adjuvants. Even after resection, GCT has a high recurrence rate <xref rid="bib0002" ref-type="bibr">[2]</xref>. The trigger for GCT is currently unknown. However, a majority of cases have cytogenetic abnormalities of telomeric associations (tas). Involvement of the RANK pathway is also believed to contribute to the pathogenesis of GCT <xref rid="bib0002" ref-type="bibr">[2]</xref>.</p></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Giant Cell Tumor</kwd><kwd>GCT</kwd><kwd>Talus</kwd></kwd-group></article-meta></front><body><sec id="sec0001"><title>Introduction</title><sec id="sec0002"><title>Case report</title><p id="para0001">A 43-year-old female with a past medical history of partial epilepsy presented for 1 month of progressive left ankle pain following a fall. Three months prior to the fall, she had twisted her ankle but did not seek medical treatment. Physical exam revealed mild edema and tenderness of the lateral left ankle. A left ankle radiograph showed a remote avulsion of the tip of the lateral malleolus, but no bone or joint abnormalities were noted. She was diagnosed with an ankle sprain (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>).<fig id="fig0001"><label>Fig. 1</label><caption><p>A remote avulsion lesion of the tip of the left lateral malleolus noted with a well corticated bone fragment.</p></caption><alt-text id="alt0001">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig></p><p id="para0002">The patient was prescribed a walking boot and physical therapy, without clinical improvement. At her 2 month follow-up visit, the physical exam revealed continued edema on the anterior and lateral aspects of the left ankle, with tenderness but no palpable mass. An MRI performed at this time demonstrated a well-circumscribed lesion of the talar neck with reactive bone marrow edema (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>).<fig id="fig0002"><label>Fig. 2</label><caption><p>MRI of the left ankle. (A) Unenhanced axial TI MRI depicting a well-circumscribed lesion in the medial aspect of the talar neck extending to the articular surface at the level of the medial facet of the subtalar joint. (B) Sagittal T1 MRI with contrast and fat suppression showing enhancement of lesion with a thin sclerotic border. (C) Unenhanced sagittal T2 demonstrates heterogenous hyperintense signal with a thin sclerotic border.</p></caption><alt-text id="alt0002">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig></p><p id="para0003">The patient underwent a CT-guided core needle biopsy which was inconclusive, but images demonstrated a well circumscribed lytic lesion in the talar neck with extension to the articular surface (<xref rid="fig0003" ref-type="fig">Fig. 3</xref>).<fig id="fig0003"><label>Fig. 3</label><caption><p>CT guided-needle biopsy demonstrating the lytic bone lesion of the talus.</p></caption><alt-text id="alt0003">Fig. 3</alt-text><graphic xlink:href="gr3"/></fig></p><p id="para0004">The needle biopsy revealed spindle cells admixed with giant cells and fibrous tissue. However, due to paucity of lesional material, was considered nondiagnostic.</p><p id="para0005">Subsequently, the patient underwent a left talus open biopsy. Intraoperative fluoroscopy was used to confirm location of the lesion (<xref rid="fig0005" ref-type="fig">Fig. 5</xref>). Frozen section analysis revealed spindle cells admixed with giant cells, fibrous tissue, and bone. No malignancy was detected, and final diagnosis was deferred until the permanent slides could be evaluated (<xref rid="fig0004" ref-type="fig">Fig. 4</xref>A).<fig id="fig0004"><label>Fig. 4</label><caption><p>(A) Left talus open biopsy specimen with an even distribution of osteoclast-like giant cells (arrow) amongst cytologically bland stromal cells. H&#x00026;E &#x000d7;100.(B) Left talus, curettage 6 months later. Photomicrograph highlights multinucleate giant cells whose nuclei resemble those of the surrounding stromal cells. H&#x00026;E &#x000d7;400.</p></caption><alt-text id="alt0004">Fig. 4</alt-text><graphic xlink:href="gr4"/></fig><fig id="fig0005"><label>Fig. 5</label><caption><p>Intraoperative bone biopsy with fluoroscopy, revealing lytic lesion on talus.</p></caption><alt-text id="alt0005">Fig. 5</alt-text><graphic xlink:href="gr5"/></fig></p><p id="para0006">The patient returned to the clinic 2 weeks after open biopsy. Pathology results were reviewed and showed GCT. The patient was counseled for the recommendation of extended intralesional curettage and use of adjuvants to appropriately treat the GCT of bone. She declined to undergo another procedure at that time. The patient was informed that nontreated GCT is progressive in nature and prone to progression with further destruction of the bone. The patient understood but declined further treatment at the time. She was maintained on nonweight bearing precautions and was advanced to weight bearing as tolerated 6 weeks after open biopsy. A radiograph was taken which demonstrated no evidence of fracture.</p><p id="para0007">At 6 months status post open biopsy of the talus, ankle radiographs demonstrated progression of disease as expected (<xref rid="fig0006" ref-type="fig">Fig. 6</xref>). Intralesional curettage and use of adjuvants was recommended, to which the patient consented.<fig id="fig0006"><label>Fig. 6</label><caption><p>Weight-bearing ankle radiograph after open biopsy demonstrating progression of Giant Cell Tumor.</p></caption><alt-text id="alt0006">Fig. 6</alt-text><graphic xlink:href="gr6"/></fig></p><p id="para0008">Follow-up CT shows increase in size of the previously seen lytic lesion now measuring (approximately 2.2&#x000a0;&#x000d7;&#x000a0;2.1&#x000a0;&#x000d7;&#x000a0;2.4 cm (AP, transverse, and CC dimension), (previously measured 1.5&#x000a0;&#x000d7;&#x000a0;1.3&#x000a0;&#x000d7;&#x000a0;1.7 cm) in the medial aspect of the talar neck) (<xref rid="fig0007" ref-type="fig">Fig. 7</xref>A).<fig id="fig0007"><label>Fig. 7</label><caption><p>(A) Unenhanced sagittal helical CT showing an interval increase in size of the 2.4 cm well-circumscribed lytic lesion, status post open biopsy. (B) Nonweight-bearing ankle radiograph immediately status postcurettage, use of adjuvants and cementation of talar lesion soft tissue edema and ankle joint effusion from surgery.</p></caption><alt-text id="alt0007">Fig. 7</alt-text><graphic xlink:href="gr7"/></fig></p><p id="para0009">The patient then underwent an extended intralesional curettage and use of adjuvants, including high-speed burr, dilute hydrogen peroxide, sterile water, and argon beam. The talus was then filled with antibiotic impregnated cement with added vancomycin. Postsurgical radiographs demonstrated cement-packing of the lesion and mild soft tissue edema (<xref rid="fig0007" ref-type="fig">Fig. 7</xref>B).</p><p id="para0010">Histological examination from the second procedure, confirmed the presence of multinucleated giant cells (<xref rid="fig0004" ref-type="fig">Fig. 4</xref>B). Postsurgical treatment plan consisted of denosumab, chest imaging, and regular ankle radiographs, to monitor for pulmonary metastasis and GCT recurrence. At 16 months after the extended curettage, there was no evidence of bone resorption around the cement or GCT recurrence (<xref rid="fig0008" ref-type="fig">Fig. 8</xref>).<fig id="fig0008"><label>Fig. 8</label><caption><p>Postextended curettage weight-bearing ankle radiograph demonstrating cement packing with no resorption or GCT recurrence at 2-year follow-up.</p></caption><alt-text id="alt0008">Fig. 8</alt-text><graphic xlink:href="gr8"/></fig></p></sec></sec><sec id="sec0003"><title>Discussion</title><p id="para0011">Giant cell tumor of the talus has been intermittently described in the past. A search of literature on GCT of the talus in PubMed revealed 28 cases of GCT of the talus, including case reports and case series. Tumors presenting in the bones of the feet have a reported incidence of 1%-2% <xref rid="bib0004" ref-type="bibr">[4]</xref>. However, a previous retrospective case series of 240 cases of GCT, found a GCT talus incidence of only 0.4% <xref rid="bib0005" ref-type="bibr">[5]</xref>. GCT is a benign bone neoplasm with characteristic multinuclear giant cells. The most common presentation is in the early twenties to forties, with a female predominance <xref rid="bib0003" ref-type="bibr">[3]</xref>. The etiology of GCT has not been elucidated completely to date.</p></sec><sec id="sec0004"><title>Radiographs</title><p id="para0012">The primary diagnosis modality for GCT is radiography. GCT is usually seen in long bones in 85% of cases, with 10% of cases reported in the axial skeleton and 1%-2% in bones of the feet <xref rid="bib0004" ref-type="bibr">[4</xref>,<xref rid="bib0006" ref-type="bibr">6]</xref>. GCT presents as a radiolucent lytic lesion with geographic bone destruction <xref rid="bib0001" ref-type="bibr">[1</xref>,<xref rid="bib0003" ref-type="bibr">3]</xref>. The tumor can develop in the medulla as well as eccentrically. Over time eccentric lesions will grow and become more centered and symmetric, especially in long bones <xref rid="bib0003" ref-type="bibr">[3]</xref>. Most commonly originating in the metaphysis, with extension into the subchondral bone plate and the epiphysis <xref rid="bib0006" ref-type="bibr">[6</xref>,<xref rid="bib0007" ref-type="bibr">7]</xref>.</p><p id="para0013">GCT will present with well-defined non-sclerotic margins in 80%-90% of cases, sometimes described as &#x0201c;moth eaten&#x0201d; <xref rid="bib0007" ref-type="bibr">[7</xref>,<xref rid="bib0008" ref-type="bibr">8]</xref>. Sclerotic margins are uncommonly seen <xref rid="bib0003" ref-type="bibr">[3]</xref>.</p><p id="para0014">Less aggressive and early lesions usually do not interfere with the cortex and have defined trabeculation <xref rid="bib0003" ref-type="bibr">[3</xref>,<xref rid="bib0009" ref-type="bibr">9]</xref>. More aggressive GCTs may present with cortical thinning and expansion, leading to periosteal elevation, and extension to surrounding tissues <xref rid="bib0006" ref-type="bibr">[6</xref>,<xref rid="bib0010" ref-type="bibr">10]</xref>. Furthermore, cortical destruction is associated with pathologic fractures during initial presentation <xref rid="bib0006" ref-type="bibr">[6]</xref>. In GCT, tumor matrix mineralization (extracellular space substance between tumor cells) is uncommon <xref rid="bib0003" ref-type="bibr">[3]</xref>. Lastly, GCT exhibits a sharp narrow zone of transition normally located at the lesion margin <xref rid="bib0002" ref-type="bibr">[2]</xref>. However, more aggressive variants may show a wide zone of transition <xref rid="bib0010" ref-type="bibr">[10]</xref>.</p><sec id="sec0005"><title>CT</title><p id="para0015">Staging, operative planning, and lesion progression assessment of GCT is commonly performed through computerized tomography imaging <xref rid="bib0003" ref-type="bibr">[3]</xref>. CT imaging also visualizes certain characteristics such as mineralization, cortical thinning, associated fractures, and extension of the lesion into soft tissues more effectively <xref rid="bib0002" ref-type="bibr">[2</xref>,<xref rid="bib0010" ref-type="bibr">10]</xref>. CT is also favored over MRI for evaluating subtle cortical destruction. The presence of fluid-fluid levels may also be observed, indicating secondary aneurysmal bone cyst formation <xref rid="bib0003" ref-type="bibr">[3]</xref>. Due to the high vascularity of GCT, tumor blush may be exhibited on contrast-enhanced CT <xref rid="bib0007" ref-type="bibr">[7]</xref>. This hypervascularity can lead to intratumoral hemorrhaging that may be seen on CT imaging as well <xref rid="bib0003" ref-type="bibr">[3]</xref>.</p></sec><sec id="sec0006"><title>MRI</title><p id="para0016">For more specific tumor characterization, MRI may be used. GCT demonstrates homogenous, low to intermediate signal lesion on T1-weighted images <xref rid="bib0003" ref-type="bibr">[3]</xref>. T1 is preferred for intramedullary tumor characterization <xref rid="bib0009" ref-type="bibr">[9]</xref>. Gadolinium administration will result in heterogenous enhancement of solid components <xref rid="bib0011" ref-type="bibr">[11]</xref>. T2-weighted imaging will demonstrate a heterogenous hyperintense lesion. This sequence is preferred for extraosseous involvement <xref rid="bib0003" ref-type="bibr">[3</xref>,<xref rid="bib0011" ref-type="bibr">11]</xref>. Additional findings can include low signal intensity for hemosiderin deposition most identifiable on gradient echo sequences and fluid-fluid levels in secondary bone cyst formation <xref rid="bib0003" ref-type="bibr">[3</xref>,<xref rid="bib0013" ref-type="bibr">13]</xref>.</p></sec><sec id="sec0007"><title>Findings of other talus lesions</title><p id="para0017">Previous cases of GCT of the talus have also presented as a radiolucent lytic lesion on radiographs, with most taking up the whole talus or body <xref rid="bib0012" ref-type="bibr">[12</xref>,<xref rid="bib0014" ref-type="bibr">[14]</xref>, <xref rid="bib0015" ref-type="bibr">[15]</xref>, <xref rid="bib0016" ref-type="bibr">[16]</xref>. Most cases displayed cortical thinning with a case showing multiple radiolucencies indicating osteolytic lesions have also been reported <xref rid="bib0012" ref-type="bibr">[12</xref>,<xref rid="bib0014" ref-type="bibr">[14]</xref>, <xref rid="bib0015" ref-type="bibr">[15]</xref>, <xref rid="bib0016" ref-type="bibr">[16]</xref>, <xref rid="bib0017" ref-type="bibr">[17]</xref>. Expansion of the lytic lesion was also commonly seen <xref rid="bib0012" ref-type="bibr">[12</xref>,<xref rid="bib0014" ref-type="bibr">14]</xref>. Other radiographic findings included, narrowed joint spaces and narrow zone of transitions. CT was beneficial for ruling out extension into soft tissues, ligaments, and capsules, as well as further characterizing cortical destruction and joint space preservation <xref rid="bib0012" ref-type="bibr">[12</xref>,<xref rid="bib0016" ref-type="bibr">16]</xref>. For cases with MRI findings, these were consistent with hypointense lesions in T1 and hyperintense lesions in T2. Enhancement of solid components was also commonly seen <xref rid="bib0014" ref-type="bibr">[14]</xref>. One case described the tumor as a solid cystic mass with multiple trabeculations, leading to a heterogenous hyperintensity on T2 <xref rid="bib0014" ref-type="bibr">[14]</xref>.</p></sec><sec id="sec0008"><title>Radiographic differentials</title><p id="para0018">Differentials for radiolucent lesions that should be considered for radiographs include chondroblastoma, chondromyxoid fibroma, enchondromas, and chondrosarcoma. Osteosarcomas and osteoblastomas are less commonly mistaken for GCT <xref rid="bib0008" ref-type="bibr">[8]</xref>. Defining characteristics of chondroblastoma include internal matrix calcification with a thin sclerotic border usually seen in the epiphysis of bones. Chondromyxoid fibroma arises will be a lobulated lucent lesion in the metaphysis with a scalloped sclerotic border <xref rid="bib0018" ref-type="bibr">[18]</xref>. Enchondromas are lytic lesions usually located in the metaphyseal region that lack aggressive features, such as a periosteal reaction, endosteal scalloping <xref rid="bib0019" ref-type="bibr">[19]</xref>. Lastly, chondrosarcomas are malignant lesions that have a unique ring-and-arc calcification pattern from chondroid matrix mineralization <xref rid="bib0020" ref-type="bibr">[20]</xref>.</p></sec><sec id="sec0009"><title>Pathological differentials</title><p id="para0019">The most prominent characteristic of GCT pathologically is the presence of multinucleated giant cells uniformly scattered with mononuclear stromal cells <xref rid="bib0010" ref-type="bibr">[10]</xref>. Immunostaining will be positive for CD45, CD68, and cathepsin K with some staining for antihistone H3.3 G34W antibody <xref rid="bib0021" ref-type="bibr">[21]</xref>.However, there are other bone lesions that contain osteoclast-like giant cells include chondroblastoma, chondromyxoid fibroma, aneurysmal bone cyst (ABC), Langerhans cell histiocytosis, and giant cell-rich osteosarcoma <xref rid="bib0018" ref-type="bibr">[18]</xref>. Chondroblastoma will have polyhedral chondroblasts, amorphous chondroid, and chicken wire pattern calcification. Few giant cells can be found scattered in chondroid matrix. Chondroblastoma will stain positive for S100 and have sometimes been found to express DOG1 <xref rid="bib0018" ref-type="bibr">[18]</xref>. ABCs have giant cells and macrophages lining cystic blood-filled spaces. Histologically, chondromyxoid fibroma has very few giant cells with fibrous tissue bands surrounding stellate cell lobules. Chondromyxoid fibroma will stain for S100, SOX9, and collagen III and express smooth muscle actin <xref rid="bib0018" ref-type="bibr">[18]</xref>. Langerhans cell histiocytosis have characteristic Langerhans cells, which are ovoid cells with a lobulated nuclei. They will contain intracytoplasmic tennis racquet-shaped inclusion bodies or Birbeck granules. The bone lesion will also contain some giant cells and eosinophil polymorphs that may form eosinophil abscesses. Langerhans cell histiocytosis will be positive for S100, CD68, HLA-DR, and Langerin <xref rid="bib0018" ref-type="bibr">[18]</xref>. Lastly, giant cell-rich osteosarcoma will present with a high number of giant cells which are evenly distributed, most characteristic by atypical mitoses and nuclear pleomorphism representing malignant features <xref rid="bib0018" ref-type="bibr">[18]</xref>.</p></sec><sec id="sec0010"><title>Treatment and prognosis</title><p id="para0020">The prognosis of GCT is favorable, only 5% of cases show pulmonary metastasis. Malignant transformation usually may occur after radiotherapy <xref rid="bib0022" ref-type="bibr">[22]</xref>. Treatment often consists of extended intralesional curettage that may include adjuvants such as phenol, high-speed burr, dilute hydrogen peroxide, sterile water, argon beam, and liquid nitrogen <xref rid="bib0007" ref-type="bibr">[7]</xref>. After curettage, reconstruction may be done with bone grafts and cementation <xref rid="bib0022" ref-type="bibr">[22]</xref>. Recurrence occurs in up to 20% of cases. A second intralesional curettage is then indicated <xref rid="bib0007" ref-type="bibr">[7]</xref>. In cases where surgery is not an option, radiation therapy or denosumab treatment may be used <xref rid="bib0022" ref-type="bibr">[22]</xref>.</p><p id="para0021">Although GCT of the bone is most often benign, there is a small risk of malignant transformation <xref rid="bib0018" ref-type="bibr">[18]</xref>. Follow-up chest radiographs are routinely performed to rule out lung metastases (seen in 1%-6% of GCT cases) <xref rid="bib0010" ref-type="bibr">[10]</xref>.</p><p id="para0022">Overall, GCT is a benign bone malignancy that has favorable prognosis after appropriate surgical intervention. Clinical signs include pain and edema over the ankle, at times with tenderness as well <xref rid="bib0016" ref-type="bibr">[16]</xref>. Early presentations may be associated with a sudden fracture. Therefore, suspicion should arise after a pathological fracture in an unusual location, to ensure early detection. The earliest recognition will often occur with a radiograph showing a lytic lesion. Further characterization of a lytic lesion is recommended when found in unexpected areas such as the talus. Careful search for other lesions is warranted, since GCT of the talus may be multicentric in small bones <xref rid="bib0016" ref-type="bibr">[16]</xref>. Further imaging to confirm the presence of GCT benefits from MR imaging. T1-weighted MRI will demonstrate a hypointense or isointense lesion that will be hyperintense on T2-weighted imaging. CT imaging is often preferred to investigate cortical destruction, extension into soft tissues, and for surgical staging and planning. After resection, repeat imaging for the appearance of pulmonary metastasis or GCT recurrence is highly encouraged.</p></sec></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name><surname>Turcotte</surname><given-names>R.E.</given-names></name></person-group><article-title>Giant cell tumor of bone</article-title><source>Orthoped Clin North Am</source><volume>37</volume><issue>1</issue><year>2006</year><fpage>35</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.ocl.2005.08.005</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name><surname>Sobti</surname><given-names>A.</given-names></name><name><surname>Agrawal</surname><given-names>P.</given-names></name><name><surname>Agarwala</surname><given-names>S.</given-names></name><name><surname>Agarwal</surname><given-names>M</given-names></name></person-group><article-title>Giant cell tumor of bone-an overview</article-title><source>Arch Bone Jt Surg</source><volume>4</volume><issue>1</issue><year>2016</year><fpage>2</fpage><lpage>9</lpage><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733230/" id="interref0002">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733230/</ext-link><comment>Accessed May 19, 2019</comment><pub-id pub-id-type="pmid">26894211</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name><surname>Purohit</surname><given-names>S.</given-names></name><name><surname>Pardiwala</surname><given-names>D.N.</given-names></name></person-group><article-title>Imaging of giant cell tumor of bone</article-title><source>Indian J Orthop</source><volume>41</volume><issue>2</issue><year>2007</year><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.4103/0019-5413.32037</pub-id><pub-id pub-id-type="pmid">21139758</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name><surname>Wilde</surname><given-names>G.E.</given-names></name><name><surname>Gakhal</surname><given-names>M.S.</given-names></name></person-group><article-title>Radiological reasoning: imaging of a talar mass</article-title><source>AJR Integr Imaging</source><volume>196</volume><year>2011</year><fpage>WS47</fpage><lpage>WS52</lpage><pub-id pub-id-type="doi">10.2214/AJR.09.7195</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Minhas</surname><given-names>M.S.</given-names></name><name><surname>Khan</surname><given-names>K.M.</given-names></name><name><surname>Muzzammil</surname><given-names>M.</given-names></name></person-group><article-title>Giant cell tumour of foot bones&#x02014;25 years experience in a tertiary care hospital</article-title><source>J Pakistan Med Assoc</source><volume>65</volume><issue>11</issue><year>2015</year><fpage>S-67-S-71</fpage></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name><surname>Van der Heijden</surname><given-names>L.</given-names></name><name><surname>Dijkstra</surname><given-names>P.D.</given-names></name><name><surname>van de Sande</surname><given-names>M.A.</given-names></name><name><surname>Kroep</surname><given-names>J.R.</given-names></name><name><surname>Nout</surname><given-names>R.A.</given-names></name><name><surname>Van Rijswijk</surname><given-names>C.S.P.</given-names></name></person-group><article-title>The clinical approach toward giant cell tumor of bone</article-title><source>Oncologist</source><volume>19</volume><issue>5</issue><year>2014</year><fpage>550</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">24718514</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name><surname>Raskin</surname><given-names>K.A.</given-names></name><name><surname>Schwab</surname><given-names>J.H.</given-names></name><name><surname>Mankin</surname><given-names>H.J.</given-names></name><name><surname>Springfield</surname><given-names>D.S.</given-names></name><name><surname>Hornicek</surname><given-names>F.J.</given-names></name></person-group><article-title>Giant cell tumor of bone</article-title><source>J Am Acad Orthop Surg</source><volume>21</volume><issue>2</issue><year>2013</year><fpage>118</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.5435/JAAOS-21-02-118</pub-id><pub-id pub-id-type="pmid">23378375</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name><surname>Stacy</surname><given-names>G.S.</given-names></name><name><surname>Peabody</surname><given-names>T.D.</given-names></name><name><surname>Dixon</surname><given-names>L.B.</given-names></name></person-group><article-title>Mimics on radiography of giant cell tumor of bone</article-title><source>Am J Roentgenol</source><volume>181</volume><issue>6</issue><year>2003</year><fpage>1583</fpage><lpage>1589</lpage><pub-id pub-id-type="pmid">14627578</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name><surname>Mavrogenis</surname><given-names>A.F.</given-names></name><name><surname>Igoumenou</surname><given-names>V.G.</given-names></name><name><surname>Megaloikonomos</surname><given-names>P.D.</given-names></name><name><surname>Panagopoulous</surname><given-names>G.N.</given-names></name><name><surname>Papagelopoulos</surname><given-names>P.J.</given-names></name><name><surname>Soucacos</surname><given-names>P.N.</given-names></name></person-group><article-title>Giant cell tumor of bone revisited</article-title><source>SICOT-J</source><volume>3</volume><issue>54</issue><year>2017</year><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598212" id="interref0003">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598212</ext-link><comment>Accessed May 19, 2019</comment></element-citation></ref><ref id="bib0010"><label>10</label><mixed-citation publication-type="other" id="othref0001">Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GR. Giant cell tumor of bone: review, mimics, and new developments in treatment. 2013; 33(1). <pub-id pub-id-type="doi">10.1148/rg.331125089</pub-id>.</mixed-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>H.M.</given-names></name><name><surname>Marchiori</surname><given-names>E.</given-names></name><name><surname>Severo</surname><given-names>A.</given-names></name></person-group><article-title>Magnetic resonance imaging aspects of giant-cell tumours of bone</article-title><source>J Med Imaging Radiat Oncol</source><volume>58</volume><issue>2014</issue><year>2014</year><fpage>674</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">25256094</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S.</given-names></name><name><surname>Wani</surname><given-names>I.H.</given-names></name><name><surname>Gupta</surname><given-names>N.</given-names></name><name><surname>Mahajan</surname><given-names>N.</given-names></name><name><surname>Salaria</surname><given-names>A.Q.</given-names></name></person-group><article-title>Giant cell tumor of talus: a case report</article-title><source>Cases J</source><volume>2</volume><issue>1</issue><year>2009</year><fpage>74</fpage><pub-id pub-id-type="doi">10.1186/1757-1626-2-74</pub-id><comment>Published 2009 Jan 21</comment><pub-id pub-id-type="pmid">19159463</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>J.M.C.</given-names></name><name><surname>Magarelli</surname><given-names>N.</given-names></name><name><surname>Peh</surname><given-names>W.C.G.</given-names></name><name><surname>Guglielmi</surname><given-names>G.</given-names></name><name><surname>Shek</surname><given-names>T.W.H.</given-names></name></person-group><article-title>Imaging of giant cell tumour of the tendon sheath</article-title><source>La radiologia medidca</source><volume>115</volume><year>2010</year><fpage>141</fpage><lpage>151</lpage><ext-link ext-link-type="uri" xlink:href="https://link.springer.com/article/10.1007%2Fs11547-010-0515-2" id="interref0005">https://link.springer.com/article/10.1007%2Fs11547-010-0515-2</ext-link></element-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name><surname>Khatoon</surname><given-names>Z.</given-names></name><name><surname>Tariq</surname><given-names>R.</given-names></name><name><surname>Kureshi</surname><given-names>S.B.</given-names></name><name><surname>Ahmed</surname><given-names>R.</given-names></name></person-group><article-title>Giant cell tumor: rare sites</article-title><source>Pakistan J Radiol</source><volume>22</volume><issue>1</issue><year>2012</year><ext-link ext-link-type="uri" xlink:href="https://pdfs.semanticscholar.org/0e85/04e6443043516fd3ad3a30035695528488c0.pdf" id="interref0006">https://pdfs.semanticscholar.org/0e85/04e6443043516fd3ad3a30035695528488c0.pdf</ext-link><comment>Accessed May 20, 2019</comment></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name><surname>Bapat</surname><given-names>M.R.</given-names></name><name><surname>Narlawar</surname><given-names>R.S.</given-names></name><name><surname>Pimple</surname><given-names>M.K.</given-names></name><name><surname>Bhosale</surname><given-names>P.B.</given-names></name></person-group><article-title>Giant cell tumour of talar body</article-title><source>J Postgrad Med</source><volume>46</volume><issue>2</issue><year>2000</year><fpage>110</fpage><lpage>111</lpage><ext-link ext-link-type="uri" xlink:href="http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2000;volume=46;issue=2;spage=110;epage=1;aulast=Bapat" id="interref0007">http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2000;volume=46;issue=2;spage=110;epage=1;aulast=Bapat</ext-link><comment>Accessed May 20, 2019</comment><pub-id pub-id-type="pmid">11013480</pub-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Bhattacharyya</surname><given-names>A.</given-names></name><name><surname>Das</surname><given-names>R.</given-names></name><name><surname>Darwani</surname><given-names>R.</given-names></name></person-group><article-title>Giant cell tumor of the talus: a case report and review of literature</article-title><source>Foot Ankle Online J</source><volume>3</volume><issue>88</issue><year>2010</year><fpage>2</fpage><ext-link ext-link-type="uri" xlink:href="http://faoj.org/2010/08/01/giant-cell-tumor-of-the-talus-a-case-report-and-review-of-literature/" id="interref0008">http://faoj.org/2010/08/01/giant-cell-tumor-of-the-talus-a-case-report-and-review-of-literature/</ext-link><comment>Accessed May 20, 2019</comment></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name><surname>Mondal</surname><given-names>S.</given-names></name><name><surname>Banik</surname><given-names>R.</given-names></name><name><surname>Sarkar</surname><given-names>A.</given-names></name><name><surname>Saha</surname><given-names>B.</given-names></name></person-group><article-title>Giant cell tumour of the talus: a rare case report</article-title><source>IOSR-JDMS</source><volume>14</volume><issue>2</issue><year>2015</year><fpage>72</fpage><lpage>74</lpage><ext-link ext-link-type="uri" xlink:href="http://www.iosrjournals.org/iosr-jdms/papers/Vol14-issue2/Version-3/P014237274.pdf" id="interref0009">http://www.iosrjournals.org/iosr-jdms/papers/Vol14-issue2/Version-3/P014237274.pdf</ext-link><comment>Accessed May 20, 2019</comment></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name><surname>Orosz</surname><given-names>Z.</given-names></name><name><surname>Athanasou</surname><given-names>N.A.</given-names></name></person-group><article-title>Giant cell-containing tumors of bone</article-title><source>Surg Pathol Clin</source><volume>10</volume><issue>3</issue><year>2017</year><fpage>553</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">28797502</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name><surname>Ferrer-Santacreu</surname><given-names>E.M.</given-names></name><name><surname>Ortiz-Cruz</surname><given-names>E.J.</given-names></name><name><surname>D&#x000ed;az-Almir&#x000f3;n</surname><given-names>M.</given-names></name><name><surname>Pozo Kreilinger</surname><given-names>J.J.</given-names></name></person-group><article-title>et al Enchondroma versus chondrosarcoma in long bones of appendicular skeleton: clinical and radiological criteria&#x02014;a follow-up</article-title><source>J Oncol</source><volume>216</volume><year>2016</year><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791495/" id="interref0010">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791495/</ext-link></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name><surname>Murphey</surname><given-names>M.D.</given-names></name><name><surname>Walker</surname><given-names>E.A.</given-names></name><name><surname>Wilson</surname><given-names>A.J.</given-names></name><name><surname>Kransdorf</surname><given-names>M.J.</given-names></name><name><surname>Temple</surname><given-names>H.T.</given-names></name><name><surname>Gannon</surname><given-names>F.H.</given-names></name></person-group><article-title>Imaging of primary chondrosarcoma: radiologic-pathologic correlation</article-title><source>AFIP Arch</source><volume>23</volume><issue>5</issue><year>2003</year><fpage>1245</fpage><lpage>1278</lpage><ext-link ext-link-type="uri" xlink:href="https://pubs.rsna.org/doi/full/10.1148/rg.235035134" id="interref0011">https://pubs.rsna.org/doi/full/10.1148/rg.235035134</ext-link></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Skubitz</surname><given-names>K.M.</given-names></name></person-group><article-title>Giant cell tumor of bone: current treatment options</article-title><source>Curr Treat Options Oncol</source><volume>15</volume><issue>3</issue><year>2014</year><fpage>507</fpage><lpage>518</lpage><ext-link ext-link-type="uri" xlink:href="https://link.springer.com/article/10.1007%2Fs11864-014-0289-1" id="interref0012">https://link.springer.com/article/10.1007%2Fs11864-014-0289-1</ext-link><comment>Accessed May 20, 2019</comment><pub-id pub-id-type="pmid">24788576</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name><surname>Puri</surname><given-names>A.</given-names></name><name><surname>Agarwal</surname><given-names>M.</given-names></name></person-group><article-title>Treatment of giant cell tumor of bone: current concepts</article-title><source>Indian J Orthop</source><volume>41</volume><issue>2</issue><year>2007</year><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.4103/0019-5413.32039</pub-id><comment>Accessed May 20, 2019</comment><pub-id pub-id-type="pmid">21139760</pub-id></element-citation></ref></ref-list></back></article>